FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210491997> ?p ?o ?g. }

• W4210491997 endingPage "340" @default.
• W4210491997 startingPage "340" @default.
• W4210491997 abstract "The swine industry has evolved significantly in the recent decades, but this has come at considerable expense to piglet survival. Breeding sows for greater prolificacy has been accompanied by a greater proportion of piglets being born underweight, of lower vigor, and higher susceptibility to early mortality. Inducing sows to farrow during working hours has the potential to increase piglet survivability, but non-therapeutic injectable products are often discouraged on farms. We aimed to design and develop a novel vaginal drug delivery system (NVDDS) that could reliably trigger luteolysis and induce parturition. To achieve this, two vaginal tablets containing the luteolytic agent cloprostenol were formulated to be inserted together: one would release constituents immediately on insertion (immediate release; IR) and the other would release cloprostenol in a controlled manner (controlled release; CR). The two formulations (IR and CR) were evaluated for drug release, swelling and bio-adhesion in conditions simulating the sow vaginal environment. The IR tablet released the drug completely for 5 min whereas the CR tablet took 5 h to release 50% of the drug. Furthermore, the release kinetics were evaluated by fitting the dissolution profiles into different mathematical models. Both IR and CR tablets were best fitted by the Makoid-Banakar model which assumes release by summation of different mechanisms. The performance of the optimized formulations was studied in vivo with 161 Large White x Landrace sows of varying parity (0-5). The sows were assigned to five groups. Group 1 (SI) received a single vulval injection of cloprostenol at 0700 h (n = 32), group 2 (SDI) received the same dose split in two parts, at 0700h and 1300h (n = 33). Group 3 (IRT) animals were administered an IR tablet at 0700h (n = 32), while group 4 (IRCRT) received both IR and CR tablets at 0700 h (n = 33). Group 5 was untreated and served as a control (n = 32). The interval to farrowing was longer (p < 0.001) for controls than for treated sows, but there were no differences among cloprostenol treatments for timing of farrowing. The finding confirms the efficacy of the NVDDS for induction of farrowing in sows." @default.
• W4210491997 created "2022-02-08" @default.
• W4210491997 creator A5010892560 @default.
• W4210491997 creator A5016934192 @default.
• W4210491997 creator A5021464106 @default.
• W4210491997 creator A5026486245 @default.
• W4210491997 creator A5046033818 @default.
• W4210491997 creator A5089852629 @default.
• W4210491997 date "2022-01-31" @default.
• W4210491997 modified "2023-10-16" @default.
• W4210491997 title "Development of a Novel Vaginal Drug Delivery System to Control Time of Farrowing and Allow Supervision of Piglet Delivery" @default.
• W4210491997 cites W1964252170 @default.
• W4210491997 cites W1966307259 @default.
• W4210491997 cites W1977133724 @default.
• W4210491997 cites W1983922826 @default.
• W4210491997 cites W1984428217 @default.
• W4210491997 cites W2000332746 @default.
• W4210491997 cites W2008895382 @default.
• W4210491997 cites W2009539533 @default.
• W4210491997 cites W2010257120 @default.
• W4210491997 cites W2030477436 @default.
• W4210491997 cites W2039401762 @default.
• W4210491997 cites W2057829841 @default.
• W4210491997 cites W2058573692 @default.
• W4210491997 cites W2060320802 @default.
• W4210491997 cites W2065595968 @default.
• W4210491997 cites W2084003965 @default.
• W4210491997 cites W2086097847 @default.
• W4210491997 cites W2112355305 @default.
• W4210491997 cites W2131783526 @default.
• W4210491997 cites W2137002405 @default.
• W4210491997 cites W2138170968 @default.
• W4210491997 cites W2164138628 @default.
• W4210491997 cites W2176536329 @default.
• W4210491997 cites W2253430155 @default.
• W4210491997 cites W2315303669 @default.
• W4210491997 cites W2569753669 @default.
• W4210491997 cites W2681336903 @default.
• W4210491997 cites W2789877574 @default.
• W4210491997 cites W2810503624 @default.
• W4210491997 cites W2948919471 @default.
• W4210491997 cites W2952648289 @default.
• W4210491997 cites W2966443064 @default.
• W4210491997 cites W3005830006 @default.
• W4210491997 cites W3006092783 @default.
• W4210491997 cites W3088495079 @default.
• W4210491997 cites W3167804902 @default.
• W4210491997 cites W4256080103 @default.
• W4210491997 cites W3046744997 @default.
• W4210491997 doi "https://doi.org/10.3390/pharmaceutics14020340" @default.
• W4210491997 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35214072" @default.
• W4210491997 hasPublicationYear "2022" @default.
• W4210491997 type Work @default.
• W4210491997 citedByCount "3" @default.
• W4210491997 countsByYear W42104919972022 @default.
• W4210491997 countsByYear W42104919972023 @default.
• W4210491997 crossrefType "journal-article" @default.
• W4210491997 hasAuthorship W4210491997A5010892560 @default.
• W4210491997 hasAuthorship W4210491997A5016934192 @default.
• W4210491997 hasAuthorship W4210491997A5021464106 @default.
• W4210491997 hasAuthorship W4210491997A5026486245 @default.
• W4210491997 hasAuthorship W4210491997A5046033818 @default.
• W4210491997 hasAuthorship W4210491997A5089852629 @default.
• W4210491997 hasBestOaLocation W42104919971 @default.
• W4210491997 hasConcept C140793950 @default.
• W4210491997 hasConcept C163588942 @default.
• W4210491997 hasConcept C178790620 @default.
• W4210491997 hasConcept C185592680 @default.
• W4210491997 hasConcept C2779820397 @default.
• W4210491997 hasConcept C2780035454 @default.
• W4210491997 hasConcept C71924100 @default.
• W4210491997 hasConcept C86803240 @default.
• W4210491997 hasConcept C98274493 @default.
• W4210491997 hasConceptScore W4210491997C140793950 @default.
• W4210491997 hasConceptScore W4210491997C163588942 @default.
• W4210491997 hasConceptScore W4210491997C178790620 @default.
• W4210491997 hasConceptScore W4210491997C185592680 @default.
• W4210491997 hasConceptScore W4210491997C2779820397 @default.
• W4210491997 hasConceptScore W4210491997C2780035454 @default.
• W4210491997 hasConceptScore W4210491997C71924100 @default.
• W4210491997 hasConceptScore W4210491997C86803240 @default.
• W4210491997 hasConceptScore W4210491997C98274493 @default.
• W4210491997 hasIssue "2" @default.
• W4210491997 hasLocation W42104919971 @default.
• W4210491997 hasLocation W42104919972 @default.
• W4210491997 hasLocation W42104919973 @default.
• W4210491997 hasLocation W42104919974 @default.
• W4210491997 hasOpenAccess W4210491997 @default.
• W4210491997 hasPrimaryLocation W42104919971 @default.
• W4210491997 hasRelatedWork W1003944735 @default.
• W4210491997 hasRelatedWork W1591778978 @default.
• W4210491997 hasRelatedWork W2026275607 @default.
• W4210491997 hasRelatedWork W2142400832 @default.
• W4210491997 hasRelatedWork W2336156617 @default.
• W4210491997 hasRelatedWork W2993084851 @default.
• W4210491997 hasRelatedWork W3091612383 @default.
• W4210491997 hasRelatedWork W4385496634 @default.
• W4210491997 hasRelatedWork W2291752956 @default.

• next